| Statistical considerations for testing multiple endpoints in group sequential or adaptive clinical trials. | |
| | |
MedLine Citation:
|
PMID: 18027226 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Many clinical trials are designed with a fixed sample size or total number of events to detect a postulated size of treatment effect on a primary efficacy endpoint. When the trial is completed and the primary efficacy endpoint achieves statistical significance, formal statistical testing of other clinically important secondary endpoints often follows in order for the statistically and clinically significant results of these endpoints to be included in the label of the test pharmaceutical product. In conventional fixed designs without any interim analysis or trial extension, these endpoints are often tested in a pre-specified hierarchical order, following the closed testing principle. This testing strategy ensures a strong control of the overall type I error. However, when trials are conducted using a group-sequential design with interim analyses or can be extended using an adaptive design with an increase of sample size or total number of events, this conventional hierarchical testing strategy may violate the closure principle and the overall type I error rate may not be controlled in the strong sense. |
| | |
Authors:
|
H M James Hung; Sue-Jane Wang; Robert O'Neill |
Related Documents
:
|
953136 - A test for randomness. 827316 - Generalisations of two tests for the detection of household aggregation of disease. 17476946 - Comparison of independent samples of high-dimensional data by pairwise distance measures. 15761916 - Evaluation by simulation of tests based on non-linear mixed-effects models in pharmacok... 20378906 - Comparison between turnaround time and cost of herpes simplex virus testing by cell cul... 6419446 - The use of a brucella protein antigen in dermal hypersensitivity as an adjunct method t... |
Publication Detail:
|
Type: Journal Article; Research Support, U.S. Gov't, P.H.S. |
Journal Detail:
|
Title: Journal of biopharmaceutical statistics Volume: 17 ISSN: 1054-3406 ISO Abbreviation: J Biopharm Stat Publication Date: 2007 |
Date Detail:
|
Created Date: 2007-11-20 Completed Date: 2008-01-17 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9200436 Medline TA: J Biopharm Stat Country: United States |
Other Details:
|
Languages: eng Pagination: 1201-10 Citation Subset: IM |
Affiliation:
|
Division of Biometrics I, OB/OTS/CDER, FDA, Silver Spring, Maryland 20993-0002, USA. hsienming.hung@fda.hhs.gov |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Clinical Trials as Topic
/
statistics & numerical data* Endpoint Determination / statistics & numerical data* Humans Probability Research Design / statistics & numerical data* Sample Size |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Analysis strategies for adaptive designs with multiple endpoints.
Next Document: Strategies for including patients recruited during interim analysis of clinical trials.